Compare Biogen Inc (BIIB) vs Fox Corp Class A (FOXA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Fox Corp Class A — how do they compare? Biogen Inc trades at $204 (market cap $30.13B), while Fox Corp Class A trades at $61.87 (market cap $24.58B). The key difference: Biogen Inc is the larger of the two by market cap, and Fox Corp Class A pays a 0.93% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | FOXA | |
|---|---|---|
Market Cap | $30.13B | $24.58B |
Sector | Health | Media |
52-Week High | $216.63 | $76.11 |
52-Week Low | $128.93 | $48.79 |
Enterprise Value | $37.20B | $27.94B |
Dividend Yield | — | 0.93% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →
